GettyImages-609179959-hero

Pediatric Dermatology at Children's Wisconsin

The Division of Pediatric Dermatology is directed by Dr. Yvonne Chiu. This team of six full-time attending physicians and four physician assistants offer unparalleled expertise and provide comprehensive services in pediatric dermatology.

The patient care practice is one of the largest in the country with more than 20,000 outpatient pediatric visits per year at Children’s Wisconsin and its regional locations. In addition to general outpatient dermatology, the division has an active inpatient consultation service and multiple multidisciplinary and specialty clinics.

Physician examining young female

Our Mission

Provide the highest-quality care for patients with pediatric skin disease.

Disseminate pediatric dermatology knowledge and inspire the next generation.

Advance pediatric dermatology through research, collaboration, and innovation.

Advocate for a healthy, equitable, and inclusive community so children can thrive.

Our Vision

To be the preeminent Pediatric Dermatology division in the nation.

 

Core Values

Compassion. Collaboration. Excellence. Respect. Growth

Pediatric Diagnosis and Treatment Specialty Areas

all
General Dermatology

The Dermatology Program at Children's Wisconsin welcomes children and adolescents with a wide range of skin conditions such as acne, birthmarks, psoriasis and nevi (moles).

Learn more about the Children's Wisconsin dermatology program

Hyperhidrosis

Sweating is a normal function that helps the body stay cool. However, some people have a medical problem that causes them to sweat too much. The medical term for this condition is hyperhidrosis.

Learn more about hyperhidrosis

Laser

Children's Wisconsin dermatologists use a pulsed dye laser to treat children with certain dermatology conditions such as blood vessels, rosacea, pyogenic granulomas and vascular anomalies.

Learn more about laser treatment

Surgery

Children's Wisconsin offers surgical skin procedures for infants, children and adolescents. We emphasize patient comfort and reducing anxiety during procedures. Following an initial consultation, procedures are scheduled with local/regional anesthesia or full anesthesia administered by a pediatric anesthesiologist. Surgeries are performed on the following types of lesions: small congenital nevi, cysts, miscellaneous nevi, atypical nevi and other skin tumors and growths.

Learn more about pediatric dermatological surgery

Pediatric Dermatology Clinic Locations

Children's Wisconsin

Children's Wisconsin - Main Campus

8915 W. Connell Ave.
Milwaukee, WI 53226

Children's Wisconsin Appleton Clinic

Children's Wisconsin Appleton Clinic

Children’s Wisconsin Appleton Clinic
2575 E. Evergreen Dr.
Appleton, WI 54913

Children's Wisconsin Delafield Clinic

Children's Wisconsin Delafield Clinic

3195 Hillside Dr.
Delafield, WI 53018

Children's Wisconsin Forest Home Clinic

Children's Wisconsin Forest Home Clinic

Children’s Wisconsin Forest Home Clinic
1432 W. Forest Home Ave.
Milwaukee, WI 53204

Children's Wisconsin Lakeside Clinic

Children's Wisconsin Kenosha Clinic

8500 75th St. Ste 101
Kenosha, WI 53142-8213

Children's Wisconsin Mequon Clinic

Children's Wisconsin Mequon Clinic

1655 W. Mequon Rd.
Mequon, WI 53092

Children's Wisconsin New Berlin Clinic

Children's Wisconsin New Berlin Clinic

4855 S. Moorland Rd.
New Berlin, WI 53151

Active Pediatric Research Studies

For more information on a study, contact Marisol Ramos at mramos@mcw.edu.
all
Longitudinal Characterization of Pediatric-Onset Morphea
This study aims to better understand the natural history and clinical features of morphea. A retrospective review of our institutional experience with this disease is combined with a prospective registry. Standardized assessments will be completed at each visit. A tissue bank consisting of blood and skin samples will be accumulated over time to allow for translational research projects in the future.
Vascular Malformations and Abnormalities of Growth
The primary goal of this pilot study is to identify potential biomarkers for patients with vascular malformations and variable clinical phenotypes that are potentially be tested in larger clinical trials. Patients with vascular malformations will be evaluated for global or mosaic growth abnormalities in an effort to assess the extent of these associations. Patients will be clinically evaluated for growth abnormalities and will have systematic molecular studies performed to detect abnormalities in the P13 kinase/AKT signaling pathway.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic Dermatitis

Principal Investigator: Kristen Holland, MD

Enrolling age: 6 months to less than 6 years

The purpose of this study is to test the effectiveness and safety of a potential new drug called lebrikizumab in children with moderate to severe atopic dermatitis, and to see how well the study drug works when used with topical medication.

Prospective, Observational, Longitudinal Study in Pediatric Patients with Moderate to Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled with Topical Prescription Therapies Or When Those Therapies Are Not Medically Advisable

Principal Investigator: Kristen Holland, MD

Enrolling age: 6 months to less than 6 years

The purpose of this study is to better characterize atopic dermatitis and document the real-world effectiveness and safety of treatments.

A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis (START UP)

Principal Investigator: Kristen Holland, MD

Enrollment age: 2 years to less than 12 years

The purpose of this study is to assess the efficacy and safety of upadacitinib, compared with dupilumab at the label-indicated dose and frequency, in pediatric subjects 2 to < 12 years of age with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment

Principal Investigator: Kristen Holland, MD

Enrollment age: 12 years and older

The purpose of the study is to evaluate a new investigational drug, amlitelimab, for the treatment of moderate-to-severe AD in children and adults who have either failed or been intolerant of treatment with either biologic therapy or oral Janus Kinase (JAK) inhibitor treatment.

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib (BMS-986165) in Adolescent Participants (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis

Principal Investigator: Kristen Holland, MD

Enrollment age: 12 years to less than 18 years

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib, a medication currently approved for 18yo and older, in children between the ages of 12 years to less than 18 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Clinical, Immunologic, and Genetic Characterization of Severe Mucocutaneous Reactions

Principal Investigator: Yvonne Chiu, MD

The goal of this multicenter study is to develop a better understanding of the cause of reactive infectious mucocutaneous eruption (RIME) and other severe blistering skin reactions. We hope that by better understanding the cause we may be able to improve care for people who are affected by these skin reactions. For more information and to express interest in participating, please visit the study website.

Development of the Morphea Activity and Damage Measure (MADM)

Principal Investigator: Yvonne Chiu, MD

Dr. Chiu is leading a team of international morphea experts to develop and validate the a new cutaneous outcome measure for morphea called the Morphea Activity and Damage Measure (MADM). The development of MADM is crucial, as the lack of effective outcome measures hampers patient care and future research efforts in morphea treatment. The ultimate goal is to identify safer and more effective therapeutic interventions for morphea, with MADM serving as a vital step towards achieving this objective.

Pediatric Dermatology Curriculum

Principal Investigator: Leah Lalor, MD

Dr. Lalor is interested in educational research. She is developing a lecture series on basic pediatric dermatology for pediatric residents.

Acne Management

Principal Investigator: Leah Lalor, MD

Series of projects regarding safe and effective treatment of acne in adolescents.